UBS Group’s Global X Scientific Beta Europe ETF SCID Stock Holding History

UBS Group’s Portfolio SCID Stock Details SCID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,342	Closed	-$75K	–	8764
2020 Q2	$75K	Sell	3,342 -4	-0.1%	-$84	﹤0.01%	5538
2020 Q1	$64K	Buy	3,346 +406	+14%	+$9.63K	﹤0.01%	5630
2019 Q4	$76K	Sell	2,940 -423	-13%	-$10.6K	﹤0.01%	6135
2019 Q3	$81K	Buy	3,363 +231	+7%	+$5.49K	﹤0.01%	5895
2019 Q2	$76K	Buy	3,132 +27	+0.9%	+$660	﹤0.01%	5589
2019 Q1	$75K	Buy	3,105 +2,390	+334%	+$56.5K	﹤0.01%	5282
2018 Q4	$16K	Buy	715 +660	+1,200%	+$16.1K	﹤0.01%	6969
2018 Q3	$1K	Buy	+55	New	+$1.5K	﹤0.01%	7896
2016 Q4	–	Sell	-350	Closed	-$8K	–	8174
2016 Q3	$8K	Hold	350	–	–	﹤0.01%	6937
2016 Q2	$8K	Buy	+350	New	+$8.13K	﹤0.01%	6924

UBS Group's SCID Position: Q3 2020 in Review

UBS Group sold out of Global X Scientific Beta Europe ETF (SCID) in Q3 2020, closing a stake of 3,342 shares — an estimated $75K sold.

UBS Group first reported a position in SCID in Q2 2016 and held it in 10 quarters. The position peaked at $81K in Q3 2019. 0 funds tracked by Wall St. Rank hold SCID as of Q3 2020.

UBS Group reported no remaining Global X Scientific Beta Europe ETF position as of Q3 2020 after selling out during the quarter.
UBS Group sold 3,342 Global X Scientific Beta Europe ETF shares in Q3 2020, an estimated $75K.
UBS Group first reported a position in Global X Scientific Beta Europe ETF in Q2 2016 and held it in 10 quarters.
UBS Group's Global X Scientific Beta Europe ETF position peaked at $81K in Q3 2019.
0 funds tracked by Wall St. Rank held Global X Scientific Beta Europe ETF as of Q3 2020.

Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.